Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

317
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
317
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

198
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
198
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

218
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
218
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. The Prognostic Impact Of Severe Grade Immune Checkpoint Inhibitor Related Pneumonitis In Non-small Cell Lung Cancer Patients

The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients

Ni Sun1,2, Ru Li2,3, Haiyi Deng2

  • 1Guangzhou Medical University, Guangzhou, Guangdong, China.

Frontiers in Oncology
|July 10, 2024

Related Experiment Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

View abstract on PubMed

Summary
This summary is machine-generated.

Severe checkpoint inhibitor-associated pneumonitis (CIP) significantly worsens prognosis for non-small cell lung cancer (NSCLC) patients, with elevated KL-6 and therapy suspension being key risk factors. Prompt resumption of anti-tumor therapy is crucial for improving outcomes in severe CIP cases.

Area of Science:

  • Oncology
  • Immunology
  • Pulmonology

Background:

  • Checkpoint inhibitor-associated pneumonitis (CIP) is a serious side effect of immune checkpoint inhibitors (ICIs) used in cancer treatment.
  • Understanding the prognostic impact and risk factors of CIP is crucial for managing non-small cell lung cancer (NSCLC) patients receiving ICIs.

Purpose of the Study:

  • To compare prognostic differences between mild and severe CIP in NSCLC patients.
  • To identify causes of death and prognostic risk factors in NSCLC patients with severe CIP.

Main Methods:

  • Retrospective study of 116 unresectable stage III or IV NSCLC patients with CIP (April 2016-August 2022).
  • Patients categorized into mild (grade 1-2) and severe (grade 3-5) CIP groups.
  • Analysis of overall survival (OS) and risk factors for poor prognosis in the severe CIP group.
Keywords:
cause of deathimmune checkpoint inhibitornon-small cell lung cancerpneumonitis

Related Experiment Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Main Results:

  • Median OS for mild CIP was 22.1 months vs. 4.4 months for severe CIP (P<0.0001).
  • In severe CIP patients with poor prognosis, death was mainly due to CIP, while tumor progression was the main cause in the good prognosis group.
  • Suspension of anti-tumor therapy and elevated KL-6 were independent risk factors for poor prognosis in severe CIP.

Conclusions:

  • Severe CIP significantly portends a poor prognosis in NSCLC patients.
  • Elevated KL-6 levels and delayed resumption of anti-tumor therapy are critical risk factors for poor outcomes in severe CIP.
  • Timely reinitiation of anti-tumor therapy is recommended for NSCLC patients with severe CIP to improve survival.
prognosis